Loading...

Emily Bergsland, MD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentMedicine
Address550 16th. Street
San Francisco CA 94158
Phone415-885-7810
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Wisconsin, Madison, WI BS 05/1985Biochemistry/Molecular Biology
    University of Minnesota, Minneapolis, MNMD06/1989Medicine
    University of California (UCSF), San FranciscoResidency 06/1992Internal Medicine
    University of California (UCSF), San Francisco06/1993Chief Residency
    University of California (UCSF), San FranciscoFellowship06/1995Medical Oncology
    University of California (UCSF), San Francisco06/1998Molecular Medicine Training Program

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Kidambi TD, Pedley C, Blanco A, Bergsland E, Terdiman JP. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series. Fam Cancer. 2017 Mar 10. PMID: 28283864.
      View in: PubMed
    2. Mulvey CK, Van Loon K, Bergsland E, Masharani U, Nakakura EK. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Pancreas. 2017 Mar; 46(3):416-426. PMID: 28187108.
      View in: PubMed
    3. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland E, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874. PMID: 28078110.
      View in: PubMed
    4. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland E. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 Nov; 45(10):1394-1400. PMID: 27171514.
      View in: PubMed
    5. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017 Jan; 35(1):14-23. PMID: 27918724.
      View in: PubMed
    6. Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland E. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016 May; 23(5):411-8. PMID: 27080472.
      View in: PubMed
    7. Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, Chen CT, Chen Z, Avila K, Weiser MR, Berger MF, Patil S, Bergsland E, Garcia-Aguilar J. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Ann Surg Oncol. 2016 Aug; 23(8):2548-55. PMID: 27020587.
      View in: PubMed
    8. Mulvey CK, Bergsland E. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors. Hematol Oncol Clin North Am. 2016 Feb; 30(1):63-82. PMID: 26614369.
      View in: PubMed
    9. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. PMID: 26603258.
      View in: PubMed
    10. Hope TA, Verdin EF, Bergsland E, Ohliger MA, Corvera CU, Nakakura EK. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging. EJNMMI Phys. 2015 Dec; 2(1):21. PMID: 26501822; PMCID: PMC4573645.
    11. Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015 Aug; 40(6):1432-40. PMID: 25820755.
      View in: PubMed
    12. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 1; 121(19):3481-90. PMID: 26177599.
      View in: PubMed
    13. Heidecker B, Moore P, Bergsland E, Merrick SH, Rao RK. Transcatheter pulmonic valve replacement in carcinoid heart disease. Eur Heart J Cardiovasc Imaging. 2015 Sep; 16(9):1046. PMID: 26003151.
      View in: PubMed
    14. Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep. 2015 Apr 28; 11(4):577-91. PMID: 25892230; PMCID: PMC4438771 [Available on 04/28/16].
    15. Bergsland E. Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts? J Clin Oncol. 2015 May 10; 33(14):1523-6. PMID: 25646187.
      View in: PubMed
    16. Bergsland E. Is more not better?: combination therapies in colorectal cancer treatment. Hematol Oncol Clin North Am. 2015 Feb; 29(1):85-116. PMID: 25475574.
      View in: PubMed
    17. Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015 Jan; 13(1):78-108. PMID: 25583772.
      View in: PubMed
    18. Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015; 92-103. PMID: 25993147.
      View in: PubMed
    19. Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland E. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect. 2015 Mar; 4(1):9-17. PMID: 25430999; PMCID: PMC4285767.
    20. Bergsland E, Nakakura EK. Neuroendocrine tumors of unknown primary: is the primary site really not known? JAMA Surg. 2014 Sep; 149(9):889-90. PMID: 25029597.
      View in: PubMed
    21. Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct; 21(5):705-14. PMID: 25012985; PMCID: PMC4295770.
    22. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland E, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80. PMID: 24448917.
      View in: PubMed
    23. Becerra CR, Salazar R, Garcia-Carbonero R, Thomas AL, Vázquez-Mazón FJ, Cassidy J, Maughan T, Castillo MG, Iveson T, Yin D, Green S, Bergsland E. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. Cancer Chemother Pharmacol. 2014 Apr; 73(4):695-702. PMID: 24488322.
      View in: PubMed
    24. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland E. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34. PMID: 24022191; PMCID: PMC3790192.
    25. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland E, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600. PMID: 23542178; PMCID: PMC3982880.
    26. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland E, Benson AB, Venook AP. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7. PMID: 23519998; PMCID: PMC3690907.
    27. Bergsland E. Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):1-3. PMID: 23391108.
      View in: PubMed
    28. Bergsland E. The evolving landscape of neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):4-22. PMID: 23391109.
      View in: PubMed
    29. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland E, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. PMID: 21552099.
      View in: PubMed
    30. Parekh JR, Wang SC, Bergsland E, Venook AP, Warren RS, Kim GE, Nakakura EK. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas. 2012 Aug; 41(6):840-4. PMID: 22781907.
      View in: PubMed
    31. Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012 Jun 1; 10(6):724-64. PMID: 22679117.
      View in: PubMed
    32. Paulson AS, Bergsland E. Systemic therapy for advanced carcinoid tumors: where do we go from here? J Natl Compr Canc Netw. 2012 Jun 1; 10(6):785-93. PMID: 22679120.
      View in: PubMed
    33. Atreya CE, Ducker GS, Feldman ME, Bergsland E, Warren RS, Shokat KM. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs. 2012 Dec; 30(6):2219-25. PMID: 22270257.
      View in: PubMed
    34. Garcia-Aguilar J, Smith DD, Avila K, Bergsland E, Chu P, Krieg RM. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011 Jul; 254(1):97-102. PMID: 21494121; PMCID: PMC3115473.
    35. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland E, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 1; 29(7):934-43. PMID: 21263089; PMCID: PMC3068065.
    36. Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland E, Donner DB, Warren RS, Nakakura EK. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site. J Surg Res. 2010 Sep; 163(1):47-51. PMID: 20599218.
      View in: PubMed
    37. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland E, Warren RS, Nakakura EK. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010 Mar; 145(3):276-80. PMID: 20231629.
      View in: PubMed
    38. Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland E, Donner DB, Warren RS, Nakakura EK. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocr Relat Cancer. 2010 Mar; 17(1):283-91. PMID: 20048018.
      View in: PubMed
    39. Ko AH, Venook AP, Bergsland E, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. PMID: 20130876.
      View in: PubMed
    40. Kulke MH, Bergsland E, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009 Jan 8; 360(2):195-7. PMID: 19129539.
      View in: PubMed
    41. Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland E, Donner DB, Warren RS, Nakakura EK. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocr Relat Cancer. 2009 Mar; 16(1):267-79. PMID: 18987169.
      View in: PubMed
    42. Wong D, Ko AH, Hwang J, Venook AP, Bergsland E, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74. PMID: 18815548.
      View in: PubMed
    43. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008 Jul 10; 26(20):3403-10. PMID: 18612155.
      View in: PubMed
    44. Bergsland E, Ko AH, Tempero MA, Whittaker K, Weber T, Fong L, Park JW, Yeh BM, Hanahan D, Venook AP. Phase 1 trial of metronomic cyclophosphamide (CTX), bevacizumab (BV) and imatinib (IM) in patients (pts) with advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):14620. PMID: 27950279.
      View in: PubMed
    45. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland E, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71. PMID: 18379729.
      View in: PubMed
    46. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland E, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52. PMID: 18181045.
      View in: PubMed
    47. Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer. 2008 Jan; 7(1):44-7. PMID: 18279576.
      View in: PubMed
    48. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland E, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007 Oct 20; 25(30):4793-9. PMID: 17947727.
      View in: PubMed
    49. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007 Aug 15; 99(16):1232-9. PMID: 17686822.
      View in: PubMed
    50. Nakakura EK, Venook AP, Bergsland E. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer? Surg Oncol Clin N Am. 2007 Jul; 16(3):639-51, x. PMID: 17606198.
      View in: PubMed
    51. Nakakura EK, Bergsland E. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region. Hematol Oncol Clin North Am. 2007 Jun; 21(3):457-73; viii. PMID: 17548034.
      View in: PubMed
    52. Ko AH, Quivey JM, Venook AP, Bergsland E, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 1; 68(3):809-16. PMID: 17363191.
      View in: PubMed
    53. Kulke MH, Bergsland E, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Aug 1; 24(22):3555-61. PMID: 16877721.
      View in: PubMed
    54. Rajpal S, Warren RS, Alexander M, Yeh BM, Grenert JP, Hintzen S, Ljung BM, Bergsland E. Pancreatoblastoma in an adult: case report and review of the literature. J Gastrointest Surg. 2006 Jun; 10(6):829-36. PMID: 16769539.
      View in: PubMed
    55. Wanebo HJ, Argiris A, Bergsland E, Agarwala S, Rugo H. Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer Metastasis Rev. 2006 Jun; 25(2):279-92. PMID: 16770540.
      View in: PubMed
    56. Bergsland E. When does the presence of the target predict response to the targeted agent? J Clin Oncol. 2006 Jan 10; 24(2):213-6. PMID: 16365177.
      View in: PubMed
    57. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland E, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85. PMID: 16344320.
      View in: PubMed
    58. Whisenant J, Bergsland E. Anti-angiogenic strategies in gastrointestinal malignancies. Curr Treat Options Oncol. 2005 Sep; 6(5):411-21. PMID: 16107244.
      View in: PubMed
    59. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland E, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9. PMID: 15999098; PMCID: PMC2361548.
    60. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005 Jun 1; 23(16):3706-12. PMID: 15867200.
      View in: PubMed
    61. Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland E, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res. 2005 Mar 1; 11(5):1791-7. PMID: 15756001.
      View in: PubMed
    62. Bergsland E. Update on clinical trials targeting vascular endothelial growth factor in cancer. Am J Health Syst Pharm. 2004 Nov 1; 61(21 Suppl 5):S12-20. PMID: 15552622.
      View in: PubMed
    63. Bergsland E. Vascular endothelial growth factor as a therapeutic target in cancer. Am J Health Syst Pharm. 2004 Nov 1; 61(21 Suppl 5):S4-11. PMID: 15552621.
      View in: PubMed
    64. Allen J, Bergsland E. Angiogenesis in colorectal cancer: therapeutic implications and future directions. Hematol Oncol Clin North Am. 2004 Oct; 18(5):1087-119, ix. PMID: 15474337.
      View in: PubMed
    65. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. Oncologist. 2004; 9 Suppl 1:36-42. PMID: 15178814.
      View in: PubMed
    66. Mohr DC, Moran PJ, Kohn C, Hart S, Armstrong K, Dias R, Bergsland E, Folkman S. Couples therapy at end of life. Psychooncology. 2003 Sep; 12(6):620-7. PMID: 12923802.
      View in: PubMed
    67. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003 May; 111(9):1287-95. PMID: 12727920; PMCID: PMC154450.
    68. Daniel D, Meyer-Morse N, Bergsland E, Dehne K, Coussens LM, Hanahan D. Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med. 2003 Apr 21; 197(8):1017-28. PMID: 12695493; PMCID: PMC2193878.
    69. Ko AH, Bergsland E, Lee GA. Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature. Dig Dis Sci. 2003 Jan; 48(1):192-6. PMID: 12645810.
      View in: PubMed
    70. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003 Jan 1; 21(1):60-5. PMID: 12506171.
      View in: PubMed
    71. Bergsland E, Venook AP. Shedding old paradigms: developing viruses to treat cancer. J Clin Oncol. 2002 May 1; 20(9):2220-2. PMID: 11980991.
      View in: PubMed
    72. Bergsland E. Molecular mechanisms underlying the development of hepatocellular carcinoma. Semin Oncol. 2001 Oct; 28(5):521-31. PMID: 11685745.
      View in: PubMed
    73. Bergsland E, Venook AP. Hepatocellular carcinoma. Curr Opin Oncol. 2000 Jul; 12(4):357-61. PMID: 10888422.
      View in: PubMed
    74. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000 Apr; 105(8):1045-7. PMID: 10772648; PMCID: PMC300842.
    75. Bullard KM, Banda MJ, Arbeit JM, Bergsland E, Young DM. Human acellular dermal matrix as a novel model of malignant epithelial cell invasion. Invasion Metastasis. 1997; 17(1):42-52. PMID: 9425323.
      View in: PubMed
    Emily's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP